



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Acasunlimab

Cat. No.:	HY-P99419
CAS No.:	2253937-12-9
Target:	PD-1/PD-L1
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Acasunlimab (GEN1046) is a bispecific antibody (bsAb) targeting PD-L1 and 4-1BB. Acasunlimab enhances T-cell and NK-cell function through conditional 4-1BB stimulation while constitutively blocking the PD-1/PD-L1 inhibitory axis. Acasunlimab can be used in research of cancer ^{[1][2]} .								
In Vitro	<p>Acasunlimab (GEN1046; 0.001-1 μM; 0-525 min) promotes interactions between dendritic cells and T cells and enhances T-cell activation^[1].</p> <p>Acasunlimab (0.001-1 μM; 48 h; PD-L1⁺ Tumor Cells) induces dose-dependent, conditional T-cell proliferation and cytokine production and enhances antigen-specific T-cell-mediated cytotoxicity^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>Acasunlimab (GEN1046; 5 mg/kg; twice weekly for three cycles) has antitumor activity and inhibits tumor growth in double knock-in (dKI) transgenic C57BL/6 mice^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Double knock-in (dKI) transgenic C57BL/6 mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>5 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection; twice weekly for three cycles</td> </tr> <tr> <td>Result:</td> <td>Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice.</td> </tr> </table>	Animal Model:	Double knock-in (dKI) transgenic C57BL/6 mice ^[1]	Dosage:	5 mg/kg	Administration:	Intravenous injection; twice weekly for three cycles	Result:	Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice.
Animal Model:	Double knock-in (dKI) transgenic C57BL/6 mice ^[1]								
Dosage:	5 mg/kg								
Administration:	Intravenous injection; twice weekly for three cycles								
Result:	Had antitumor activity in double knock-in (dKI) transgenic C57BL/6 mice.								

REFERENCES

[1]. Muik A, et, al. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. *Cancer Discov.* 2022 May 2;12(5):1248-1265.

[2]. Gao Y, et, al. Development and characterization of a novel human CD137 agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. *FEBS Open Bio.* 2022 Dec;12(12):2166-2178.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA